Evidence map›Paper›PMID 35289408›Full record

ArticleClinical cardiology2022

Cardiovascular event rate and death in high-risk secondary prevention patient cohort in Finland: A registry study.

Iiro Toppila, Liisa Ukkola-Vuoti, Julia Perttilä, Outi Törnwall, Juha Sinisalo, Juha Hartikainen, Seppo Lehto

Abstract read
In one paragraph

Article in Clinical cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Iiro ToppilaMedaffcon Oy, Espoo, Finland.
Liisa Ukkola-VuotiMedaffcon Oy, Espoo, Finland.ORCID http://orcid.org/0000-0002-0770-361X
Julia PerttiläAmgen AB, Espoo, Finland.
Outi TörnwallBC Platforms AG, Zürich, Switzerland.
Juha SinisaloHeart and Lung Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland.
Juha HartikainenHeart Center, Kuopio University Hospital and School of Medicine, University of Eastern Finland, Kuopio, Finland.
Seppo LehtoDepartment of Internal Medicine, Lapland Central Hospital, Rovaniemi, Finland.

Funding

Amgen FinlandAmgen Inc.
6 · The paper itself

Abstract

backgroundA large number of patients are living with atherosclerotic cardiovascular (CV) disease and thus are at risk of life-threatening CV events. HYPOTHESIS: This study evaluated the risk for a recurrent CV event or death in Finnish real-world data.

methodsPatients with an incident atherosclerotic CV event between 2012 and 2016 were included in this retrospective registry study and followed for recurrent CV events or death. The risk and risk factors of recurrent CV events or death and time from the first CV event to recurrence were assessed.

resultsA total of 48,405 patients were followed from their first CV event. The event rate was 14.34 events per 100 patient-years. Multistate models suggested that at 5 years post index CV event, 41.5% of the patients had died or suffered a recurrent CV event. Death was the most common type of subsequent event (61.5%). After the first CV event, there were rapid increases both in recurrent CV events and deaths during the next 6 months. The subsequent CV event was usually of the same type as the first, which was of the cardiac or cerebrovascular cluster.

conclusionsThe incidence of recurrent CV events and all-cause mortality was high in patients suffering from their first CV event, particularly during the first 6 months after the index event. Death was the most common subsequent event. The event rate accelerated after each additional CV event. This suggests that the acute treatment of the index event should be followed by prompt secondary prevention measures to achieve guideline-recommended goals as soon as possible.

Indexed as

AtherosclerosisCardiovascular DiseasesFinlandHumansRegistriesRetrospective StudiesRisk FactorsSecondary Preventionatherosclerosiscardiovascular diseasescardiovascular risk factorsmyocardial infarctionreal-world evidenceretrospective studysecondary prevention

Identifiers

PMID35289408
PMCPMC9019873

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.